Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Hollis-Eden Pharm. (NasdaqNM:HEPH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports
Location
9333 Genesee Avenue, Suite 200
San Diego, CA 92121
Phone: (858) 587-9333
Fax: (858) 558-6470
Employees (last reported count): 35
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 54%
·Over the last 6 months:
 · one insider buy; 3,000  shares
·Institutional: 8% (17% of float)
(14 institutions)
·Net Inst. Selling: 83.0K shares (+10.45%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Hollis-Eden Pharmaceuticals Inc., a development-stage pharmaceutical company, is engaged in the discovery, development and commercialization of products for the treatment of infectious diseases and immune system disorders, including HIV/AIDS, hepatitis B and C and malaria. The Company is focusing its initial development efforts on a potent series of immune regulating hormones and hormone analogs. The Company's lead compound in this series, HE2000, is currently in Phase II clinical studies in HIV. In addition, through its relationship with Aeson Theraputics, Inc., the Company has a right to acquire significant additional intellectual property in this field, including the rights to a compound in this class that is in Phase II clinical trials for the treatment of cardiovascular disease and actinic keratosis, a precursor to squamous cell cancer.
More from Market Guide: Expanded Business Description

Financial Summary
HEPH is a development-stage pharmaceutical company engaged in the discovery, development, and commercialization of products for the treatment of a number of diseases including HIV/AIDS, hepatitis and malaria. For the six months ended 6/30/01, the Company reports no revenues. Net loss decreased 26% to $7.4 million. Results reflect decreased research and development costs related to common stock, option, and warrants grants for collaborations.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Richard Hollis, 48
Chairman, Pres, CEO
$768K
Daniel Burgess, 39
COO and Chief Financial Officer
288K
Thomas Charles Merigan, Jr., M.D., 67
Scientific Advisor
--  
James Frincke, Ph.D., 50
Exec. VP of R&D
240K
Robert Weber, 50
VP, Controller, CAO
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:HEPHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 3-Apr-2001
$2.125
Recent Price$4.64 
52-Week High
on 5-Sep-2000
$13.063
Beta1.22 
Daily Volume (3-month avg)37.3K
Daily Volume (10-day avg)20.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-55.0%
52-Week Change
relative to S&P500
-39.6%
Share-Related Items
Market Capitalization$53.9M
Shares Outstanding11.6M
Float5.30M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.17 
Earnings (ttm)-$0.69 
Earnings (mrq)-$0.33 
SalesN/A 
Cash (mrq)$2.36 
Valuation Ratios
Price/Book (mrq)2.14 
Price/EarningsN/A 
Price/SalesN/A 
Income Statements
Sales (ttm)$0 
EBITDA (ttm)-$9.95M
Income available to common (ttm)-$8.01M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-22.65%
Return on Equity (ttm)-24.39%
Financial Strength
Current Ratio (mrq)8.45 
Debt/Equity (mrq)0 
Total Cash (mrq)$27.5M
Short Interest
As of 8-Aug-2001
Shares Short64.0K
Percent of Float1.2%
Shares Short
(Prior Month)
73.0K
Short Ratio2.91 
Daily Volume22.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.